光韻達(300227.SZ):發行股份及支付現金購買資產申請獲證監會註冊批覆
格隆匯 11 月 12日丨光韻達(300227.SZ)公佈,公司於2020年11月12日收到中國證監會於2020年11月5日出具的《關於同意深圳光韻達光電科技股份有限公司向陳徵宇等發行股份購買資產並募集配套資金註冊的批覆》(證監許可【2020】2915號),同意你公司向陳徵宇發行1665.6126萬股股份、向俞嚮明發行581.0276萬股股份、向張智勇發行206.5876萬股股份、向張翕發行129.1172萬股股份購買相關資產的註冊申請。同意你公司發行股份募集配套資金不超過1.96億元的註冊申請。批覆自同意註冊之日起12個月內有效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.